You are looking for

COVID-19 dampened global trade in medical technology products. So, when we compiled the latest edition of MedTech Europe Facts & Figures (F&F), we knew readers would be keen to see whether the sector had rebounded. (Spoiler alert: it has!) F&F is the ‘go to’ guide to Europe’s medical technology sector. Packed with robust data drawn […]

Many public health campaigns focus on the importance of identifying and acting on the symptoms of major cardiovascular disease (CVD) events, such as heart attacks and strokes, as quickly as possible. Medicine has developed so much in recent decades that these events, which were once a death sentence for the majority, are now often survivable […]

Medtek Norge and Lab Norge are merging to create a new medical technological association representing 150 companies. Together, Melanor’s members have a joint turnover of around 12 billion NOK (€1.24 billion). Employing 3,000 people in Norway alone, member companies cover supplies, medical technology, laboratory equipment, welfare technology, and aids for people with disabilities. Our members’ […]

This blog is part 3 of a series on the MEAT value-based procurement project, an initiative that advocates towards a shift from price-based procurement of medical technology towards value-based procurement. It does so by defining a Most Economically Advantageous Tendering (MEAT) framework that includes the value of medical technologies, services and solutions in procurement processes […]

In September 2013 I went for a truly inspirational bike trip across 5 countries, covering over 2100 km from Brussels to Barcelona. Many of my fellow cyclists were Type 1 diabetics and the trip was organized to give insight into how issues of interoperability can be resolved.
The fundamental problem facing people with diabetes (PWD) is keeping their Blood Glucose (BG) levels within a normal range. To do this PWD use devices to monitor their BG levels. These devices provide a reading that is then used to make therapeutic decisions such as taking insulin or treating a low reading by eating.

According to EDMA’s 2012 European In Vitro Diagnostics (IVD) Market Statistics Report, the in vitro diagnostics market in Europe has decreased 2.2% in 2012. These results had been predicted in the previous EDMA report released for 2011, given austerity measures to cut costs in health expenditure. However, a decline in revenue for IVDs might have bad effects in the health of Europeans: there is good reason to believe that governments should invest in IVDs when trying to save money in healthcare.